CM. Read why NTLA stock has potential with upcoming 2025 data and a growing $12B market for Transthyretin Amyloidosis.
Based on the terms of the agreement, BridgeBio will receive a $30 million milestone payment upon approval in Japan, as well ...
The FDA recently approved the first treatment in nearly 30 years for acute stroke, and the agency also approved a novel drug ...
With drugs on the horizon for treating and possibly preventing transthyretin amyloid cardiomyopathy, cardiologists are ...
The FDA bestows a Regenerative Medicine Advanced Therapy tag to Intellia's nex-z for treating transthyretin amyloidosis with cardiomyopathy.
Genetic diseases company BridgeBio Pharma has announced that the Japanese Ministry of Health, Labor and Welfare has approved ...
BridgeBio Pharma (BBIO) announced the Japanese Ministry of Health, Labour and Welfare, MHLW, has approved acoramidis, under the brand name ...
In the Japanese Phase 3 study, 0% mortality was reported over the 30-month treatment period and acoramidis was well-tolerated ...
Hitting out at BRS, Telangana Chief Minister A Revanth Reddy on Wednesday alleged that the main opposition party is hurting the state’s interests as it seeks to show the Congress government as a ...
Amvuttra operates via RNA interference (RNAi), a groundbreaking technology that inhibits the production of the TTR protein in ...
Zacks Investment Research on MSN2d
Biotech Stock Roundup: SAVA Dives on Setback, ALNY Up on Update & MoreIt was a busy week in the biotech sector with important regulatory and pipeline updates. Among these, Cassava Sciences, Inc ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback